Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
Guido Ghilardi(Hospital of the University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Alexander A. Shestov(University of Pennsylvania), Elise A. Chong(Hospital of the University of Pennsylvania), Linhui Chen(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Giulia Gabrielli(University of Turin), Hatcher J. Ballard(University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), Emeline R. Chong(Hospital of the University of Pennsylvania), James N. Gerson(UPMC Hillman Cancer Center), Daniel J. Landsburg(University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Ellen Napier(Hospital of the University of Pennsylvania), Patrizia Porazzi(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Raymone Pajarillo(Hospital of the University of Pennsylvania), Michael C. Milone(University of Pennsylvania), Sunita D. Nasta(University of Pennsylvania), David Porter(University of Pennsylvania), Elizabeth Weber(Hospital of the University of Pennsylvania), Jordan Carter(Hospital of the University of Pennsylvania), Roderick O’Connor(University of Pennsylvania), Ivan Cohen(Hospital of the University of Pennsylvania), Vrutti Patel(Hospital of the University of Pennsylvania), Jakub Svoboda(UPMC Hillman Cancer Center), Griffin White(Hospital of the University of Pennsylvania), Rebecca Yelton(University of Pennsylvania)
Cited by 30
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
|American Journal of Hematology|2019|608
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554